WINT - Dosing underway in Windtree Therapeutics's mid-stage istaroxime study in heart disease

Windtree Therapeutics (WINT) has dosed the first patient in its Phase 2 study of istaroxime in patients experiencing early cardiogenic shock, a life-threatening state of lack of heart function and blood flow to vital organs.The 60-subject study's primary endpoint is the change in systolic blood pressure over six hours after initiating the infusion. Secondary endpoints will include characterization of blood pressure changes over 24 hours, the number of patients requiring rescue therapy, assessment of renal function and measures associated with safety and tolerability.Data from the istaroxime Phase 2 program in acute heart failure showed that istaroxime significantly improved cardiac function and increased systolic blood pressure.Isstaroxime is a dual mechanism therapy designed to improve both systolic diastolic cardiac function.

For further details see:

Dosing underway in Windtree Therapeutics's mid-stage istaroxime study in heart disease